Literature DB >> 15739898

Glyceride derivatives as potential prodrugs: synthesis, biological activity and kinetic studies of glyceride derivatives of mefenamic acid.

M S Y Khan1, M Akhter.   

Abstract

In order to reduce the gastrointestinal side effect, of mefenamic acid, its carboxylic group was condensed with the hydroxyl group of 1,2,3-trihydroxy propane 1,3-dipalmitate/stearate to give 3a and 3b. These compounds were evaluated for their gastric toxicity, anti-inflammatory activity by the carageenan induced paw oedema test and analgesic activity by the acetic acid induced writhing method. The release of mefenamic acid from the esters 3a and 3b was studied at pH 3, 4, 5 and 7.4 with direct analysis by reverse phase HPLC using acetonitrile:acetate buffer (0.1 M, pH 3.5): methanol (40:25:35) at 1 mL/min. The prodrugs showed less hydrolysis at pH 5 compared to pH 7.4 indicating that the prodrugs do not dissociate at stomach pH but release mefenamic acid at pH 7.4 in adequate amounts. The hydrolysis studies were also performed in rat plasma. A higher plasma concentration of mefenamic acid was observed in animals treated with 3a and 3b compared to the animals treated with the parent drug, and even after 8 h the concentration of mefenamic acid was 2 times higher. The peak plasma concentration of mefenamic acid in animals treated with mefenamic acid was attained in 1.5 h compared with 2 h in the case of prodrugs treated animals. The prodrugs showed less gastric ulceration compared to mefenamic acid at 100 mg/kg, a severity index of 1.10, 1.22 being observed with 3a, 3b and with mefenamic acid a severity index of 2.37 was observed. The prodrugs showed better anti-inflammatory activity compared to the parent drug and analgesic activity comparable to the parent drug. These findings suggest that the prodrugs 3a and 3b synthesized might be used as biolabile prodrugs of mefenamic acid with increased bioavailability and less gastrointestinal side effects.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15739898

Source DB:  PubMed          Journal:  Pharmazie        ISSN: 0031-7144            Impact factor:   1.267


  5 in total

1.  Studies on mefenamic acid microparticles: formulation, in vitro release, and in situ studies in rats.

Authors:  Ferhan Sevgi; Aysu Yurdasiper; Buket Kaynarsoy; Ezgi Turunç; Tamer Güneri; Ayfer Yalçin
Journal:  AAPS PharmSciTech       Date:  2009-01-29       Impact factor: 3.246

Review 2.  Liposomal delivery systems for intestinal lymphatic drug transport.

Authors:  Hyeji Ahn; Ji-Ho Park
Journal:  Biomater Res       Date:  2016-11-23

Review 3.  Intestinal lymphatic transport for drug delivery.

Authors:  Jaime A Yáñez; Stephen W J Wang; Ian W Knemeyer; Mark A Wirth; Kevin B Alton
Journal:  Adv Drug Deliv Rev       Date:  2011-06-13       Impact factor: 15.470

Review 4.  Microbial Lipases and Their Potential in the Production of Pharmaceutical Building Blocks.

Authors:  César A Godoy; Juan S Pardo-Tamayo; Oveimar Barbosa
Journal:  Int J Mol Sci       Date:  2022-09-01       Impact factor: 6.208

5.  Pharmacological evaluation and preliminary pharmacokinetics studies of a new diclofenac prodrug without gastric ulceration effect.

Authors:  Jean Leandro Dos Santos; Vanessa Moreira; Michel Leandro Campos; Rafael Consolin Chelucci; Karina Pereira Barbieri; Pollyana Cristina Maggio de Castro Souto; Márcio Hideki Matsubara; Catarina Teixeira; Priscila Longhin Bosquesi; Rosângela Gonçalves Peccinini; Chung Man Chin
Journal:  Int J Mol Sci       Date:  2012-11-19       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.